Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleuk… Read more
Medicenna Therapeutics Corp (MDNAF) - Net Assets
Latest net assets as of September 2025: $10.24 Million USD
Based on the latest financial reports, Medicenna Therapeutics Corp (MDNAF) has net assets worth $10.24 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.04 Million) and total liabilities ($7.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $10.24 Million |
| % of Total Assets | 56.77% |
| Annual Growth Rate | N/A |
| 5-Year Change | -49.94% |
| 10-Year Change | 750.6% |
| Growth Volatility | 405.14 |
Medicenna Therapeutics Corp - Net Assets Trend (2014–2025)
This chart illustrates how Medicenna Therapeutics Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medicenna Therapeutics Corp (2014–2025)
The table below shows the annual net assets of Medicenna Therapeutics Corp from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $19.09 Million | +267.85% |
| 2024-03-31 | $5.19 Million | -82.40% |
| 2023-03-31 | $29.49 Million | +41.52% |
| 2022-03-31 | $20.84 Million | -45.38% |
| 2021-03-31 | $38.15 Million | +5.52% |
| 2020-03-31 | $36.15 Million | +1281.55% |
| 2019-03-31 | $2.62 Million | +21.03% |
| 2018-03-31 | $2.16 Million | -67.52% |
| 2017-03-31 | $6.66 Million | +196.53% |
| 2016-03-31 | $2.24 Million | +11729.16% |
| 2015-03-31 | $-19.30K | +92.77% |
| 2014-03-31 | $-267.05K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medicenna Therapeutics Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11743465500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $137.35 Million | 719.28% |
| Total Equity | $19.09 Million | 100.00% |
Medicenna Therapeutics Corp Competitors by Market Cap
The table below lists competitors of Medicenna Therapeutics Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Samick Thk
KO:004380
|
$42.11 Million |
|
Farmers and Merchants Bancshares Inc
PINK:FMFG
|
$42.13 Million |
|
GIGANTE SALMON AS NK 1
F:96M
|
$42.14 Million |
|
Inmax Holding Co Ltd
TWO:1591
|
$42.14 Million |
|
LumenRadio AB
ST:LUMEN
|
$42.11 Million |
|
Pettenati S.A. Industria Têxtil
SA:PTNT3
|
$42.08 Million |
|
Skyline Builders Group Holding Limited Class A Ordinary Shares
NASDAQ:SKBL
|
$42.08 Million |
|
THiRA-UTECH CO. LTD
KQ:322180
|
$42.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medicenna Therapeutics Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,191,000 to 19,095,000, a change of 13,904,000 (267.8%).
- Net loss of 11,805,000 reduced equity.
- New share issuances of 19,714,000 increased equity.
- Other factors increased equity by 5,995,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.80 Million | -61.82% |
| Share Issuances | $19.71 Million | +103.24% |
| Other Changes | $6.00 Million | +31.4% |
| Total Change | $- | 267.85% |
Book Value vs Market Value Analysis
This analysis compares Medicenna Therapeutics Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.62x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.83x to 2.62x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-03-31 | $0.77 | $0.64 | x |
| 2021-03-31 | $0.71 | $0.64 | x |
| 2022-03-31 | $0.37 | $0.64 | x |
| 2023-03-31 | $0.42 | $0.64 | x |
| 2024-03-31 | $0.07 | $0.64 | x |
| 2025-03-31 | $0.24 | $0.64 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medicenna Therapeutics Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -61.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.49x
- Recent ROE (-61.82%) is above the historical average (-121.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-739.07K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-831.56K |
| 2016 | -59.43% | 0.00% | 0.00x | 2.56x | $-1.56 Million |
| 2017 | -114.64% | 0.00% | 0.00x | 2.18x | $-8.30 Million |
| 2018 | -345.33% | 0.00% | 0.00x | 2.02x | $-7.68 Million |
| 2019 | -179.93% | 0.00% | 0.00x | 1.98x | $-4.97 Million |
| 2020 | -22.90% | 0.00% | 0.00x | 1.05x | $-11.89 Million |
| 2021 | -45.32% | 0.00% | 0.00x | 1.11x | $-21.10 Million |
| 2022 | -108.36% | 0.00% | 0.00x | 1.13x | $-24.66 Million |
| 2023 | -34.08% | 0.00% | 0.00x | 1.24x | $-13.00 Million |
| 2024 | -490.58% | 0.00% | 0.00x | 3.69x | $-25.99 Million |
| 2025 | -61.82% | 0.00% | 0.00x | 1.49x | $-13.71 Million |
Industry Comparison
This section compares Medicenna Therapeutics Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medicenna Therapeutics Corp (MDNAF) | $10.24 Million | 0.00% | 0.76x | $42.11 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |